Positive Phase III results for Vesneo in treatment of Glaucoma and Ocular Hypertension - Bausch + Lomb/Nicox
Valeant Pharmaceuticals International, Inc.�s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. announced positive top-line results from the pivotal Phase III studies conducted with Vesneo (latanoprostene bunod; previously known as BOL-303259-X and NCX 116) for the reduction of intraocular pressure (IOP) in patients with Glaucoma or Ocular Hypertension. Vesneo is a novel nitric oxide-donating prostaglandin F2-alpha analog licensed by Nicox to Bausch + Lomb.
These studies met their primary endpoint and showed positive results on a number of secondary endpoints. Bausch + Lomb expects to submit a new drug application to the FDA for the approval of Vesneo in mid-2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.